Congruence Therapeutics
Congruence Therapeutics is a clinical-stage biotech using its Revenir™ computational platform to design oral small molecule correctors for protein misfolding diseases, with lead asset CGX-926 in Phase 1/1b for MC4R-deficient genetic obesity and pipeline programs in GBA1-Parkinson's and Alpha-1 antitrypsin deficiency.
- Company typePrivate
- Founded2022
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Congruence Therapeutics does
Congruence Therapeutics is a clinical-stage biotechnology company founded in February 2022 by Clarissa Desjardins (formerly founder/CEO of Clementia Pharmaceuticals, sold to Ipsen for US$1.31 billion in 2019) and headquartered in Montreal, Canada with a US subsidiary in Chapel Hill, North Carolina. The company develops oral small molecule "correctors" designed to stabilize misfolded proteins, restore proper folding and trafficking, and recover biological function — initially targeting three indications with no approved disease-modifying therapies: MC4R-deficient genetic obesity (lead asset CGX-926, in Phase 1/1b as of March 2026), GBA1-driven Parkinson's disease, and Alpha-1 antitrypsin deficiency.
Its core technology is the proprietary Revenir™ computational drug discovery engine, which generates and captures the biophysical properties of full protein-conformer ensembles from a single amino acid sequence to identify allosteric and cryptic pockets unsuitable for conventional static-structure methods. The platform combines machine learning, mathematical modeling, computational chemistry, and biophysics to virtually screen novel chemical matter for hit-to-lead generation, and is supported by collaborations with Mila (AI research institute) and OpenFold. Lead candidate CGX-926 has demonstrated dose-dependent body weight and food intake reduction in MC4R-deficient mouse models while preserving lean mass; GCase activators have shown activity in patient-derived neurons and GBA1 mutant mice; A1AT correctors have shown activity in cellular and transgenic mouse assays.
Congruence is pre-revenue and operates a hybrid model: it runs its own clinical trials (CGX-926 Phase 1/1b conducted through Quotient Sciences and University of Cambridge), monetizes its discovery platform via multi-target research collaborations with pharmaceutical partners (notably Ono Pharmaceutical in oncology, neurology, and immunology, plus an undisclosed global pharma in metabolic disease), and receives non-dilutive grant funding (US$5M from The Michael J. Fox Foundation). Anticipated future revenue derives from licensing upfronts, research funding, milestone payments, and tiered royalties from these partnerships, with potential longer-term direct commercialization of proprietary assets. The company has raised approximately US$139.5 million since inception from a syndicate including OrbiMed, Dimension, Amplitude Ventures, FSTQ, Lumira Ventures, BDC Capital Thrive Venture Fund, Investissement Québec, Silver Arc, Driehaus, and Alexandria.
Congruence Therapeutics firmographics
Firmographics- Name
- Congruence Therapeutics
- Legal name
- Congruence Therapeutics Inc.
- Website
- https://congruencetx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Congruence Therapeutics is a clinical-stage biotech using its Revenir™ computational platform to design oral small molecule correctors for protein misfolding diseases, with lead asset CGX-926 in Phase 1/1b for MC4R-deficient genetic obesity and pipeline programs in GBA1-Parkinson's and Alpha-1 antitrypsin deficiency.
- Ownership category
- akta.pro rank
Congruence Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Congruence Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Congruence Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Licensing and Royalties: Future revenue anticipated from licensing deals and royalty streams from pharmaceutical partnerships. Congruence receives upfront payments, research funding, milestone payments tied to discovery, development, approval, and commercialization progress, plus tiered royalties on net sales from product candidates developed through partnerships (e.g., Ono Pharmaceutical collaboration).
- Drug Sales (Future): Pre-revenue clinical stage company. Anticipated future revenue from commercialization of proprietary drug candidates including CGX-926 for genetic obesity, GCase programs for Parkinson's disease, and A1AT programs for alpha-1 antitrypsin deficiency.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Congruence Therapeutics product offering
Product offeringCore offering
Congruence Therapeutics is a clinical-stage biotechnology company developing oral small molecule correctors that stabilize misfolded proteins to address the root causes of protein misfolding diseases. Its lead asset CGX-926 (oral MC4R corrector for genetic obesity) entered Phase 1/1b clinical trials in March 2026, with additional programs targeting GBA1-driven Parkinson's disease and Alpha-1 antitrypsin deficiency. Drug candidates are discovered using the proprietary Revenir™ computational platform and advanced through strategic partnerships with large pharmaceutical companies such as Ono Pharmaceutical.
Product overview
Congruence Therapeutics is a clinical-stage biotechnology company developing a pipeline of small molecule corrector drugs targeting protein misfolding diseases. The core technology platform is Revenir™, a computational drug discovery engine that uses machine learning and biophysics to identify drug targets. The proprietary pipeline includes CGX-926 (MC4R corrector for genetic obesity, Phase 1), GCase activator/corrector programs (GBA-Parkinson's disease), and A1AT corrector program (alpha-1 antitrypsin deficiency). The company also deploys its Revenir™ platform through strategic collaborations with major pharmaceutical companies including Ono Pharmaceutical (oncology, neurology, immunology) and an undisclosed global pharma company (metabolic disease).
Differentiator
Problem solved
Functional benefit
Products and services
- CGX-926 First-in-class oral small molecule corrector of the melanocortin-4 receptor (MC4R) for treating MC4R-deficient genetic obesity, addressing receptor misfolding and impaired trafficking to restore receptor function in patients with severe hyperphagia and early-onset obesity. Currently in Phase 1/1b clinical development.
- GCase Activator/Corrector Program Orally active and brain-penetrant small molecule pharmacological activators and correctors of glucocerebrosidase (GCase) designed to restore lysosomal GCase activity for the treatment of GBA1-driven Parkinson's disease, representing approximately 100,000 patients in the US.
- A1AT Corrector Program Orally active small molecule correctors of alpha-1 antitrypsin (A1AT) that stabilize the mutant Z-AAT protein, prevent polymerization in hepatocytes, and increase secretion of functional A1AT into plasma for the treatment of Alpha-1 antitrypsin deficiency, affecting approximately 80,000-100,000 patients in the US.
- Revenir™ Product Engine Proprietary computational drug discovery engine that captures biophysical changes caused by mutations in proteins, examining surface features and biophysical descriptors of mutated and wild-type proteins to identify allosteric and cryptic pockets. Used internally for pipeline generation and deployed externally through multi-target pharmaceutical collaborations such as the Ono Pharmaceutical agreement.
Quantifiable outcome
- CGX-926 demonstrated dose-dependent reduction in body weight and food consumption in MC4R-deficient genetic obesity mouse model while preserving lean muscle mass
- +3 more outcomes
Companies that use Congruence Therapeutics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Congruence Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Congruence Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Quotient SciencesminorQuotient Sciences contracted to conduct CGX-926 Phase 1/1b clinical trial using their Translational Pharmaceutics® platform to evaluate safety, tolerability, and pharmacokinetics while enabling early efficacy evaluation.
- University of CambridgeminorDr. Sadaf Farooqi, Professor of Metabolism and Medicine at University of Cambridge, serves as principal investigator for Phase 1b trial of CGX-926 in participants with MC4R gene mutations. The trial evaluates efficacy in patients with MC4R-deficient obesity.
- Undisclosed Global Pharmaceutical CompanyminorResearch collaboration with undisclosed large pharmaceutical company targeting a difficult-to-treat metabolic disease. Congruence leveraging Revenir™ platform to discover small molecule correctors for a validated target in metabolic disease.
- Ono Pharmaceutical Co., Ltd.coreExpanded multi-target research collaboration originally focused on oncology (December 2024) to now include neurology and immunology (March 2026). Congruence uses its Revenir™ platform to discover small molecule modulators against multiple protein targets. Ono obtains exclusive worldwide option rights for development, manufacturing, and commercialization. Congruence receives upfront payment, research funding, milestone payments tied to research, development, and commercialization progress, plus tiered royalties on net sales.
Scale indicators9 records
Recent moves6 records
Expansion highlights8 records
Congruence Therapeutics competitors and assessment
Company assessmentDirect peers
- Schrödinger: Public computational drug discovery platform combining physics-based molecular simulation with ML. Directly comparable to Congruence's Revenir™ platform approach and similarly pursues both internal pipeline and platform-licensing economics.
- Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with ML to identify novel targets. Comparable pipeline structure with multiple internal programs and a platform-licensing motion similar to Congruence's.
- Insitro: ML-driven drug discovery company combining induced pluripotent stem cell biology with machine learning. Comparable technology stack and clinical-stage profile, though focused more on neuroscience and metabolic disease.
- Crinetics Pharmaceuticals: Clinical-stage biotech developing oral small molecule somatostatin receptor ligands for rare endocrine diseases including acromegaly and congenital hyperinsulinism. Directly comparable in MC4R pathway relevance and rare disease small molecule focus.
- Structure Therapeutics: Clinical-stage oral small molecule biologics platform developing oral GLP-1R agonists for obesity and cardiometabolic disease. Highly comparable therapeutic area overlap with CGX-926 and similar oral small molecule strategy for difficult targets.
- Exscientia: AI-driven drug discovery company using precision design to develop small molecule therapeutics. Comparable platform-play model with multiple internal and partnered programs across therapeutic areas.
- Nimbus Therapeutics: Computational structure-based drug design company developing selective small molecules. Comparable in applying computational chemistry to historically difficult targets and maintaining both internal pipeline and pharma partnerships.
- Atomwise: AI-based small molecule drug discovery company using structure-based convolutional neural networks. Comparable in deploying AI/ML platform to identify small molecule hits across multiple targets with pharma partnership economics.
Broad incumbents
- Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapeutics for neurodegeneration. Broader and more established player in CNS drug development, including GBA-Parkinson's programs that overlap with Congruence's second indication.
Emerging players
- Maze Therapeutics: Genetic disease drug discovery company using variant-to-function genomics to identify targets for small molecule and biologic development. Comparable in applying computational approaches to monogenic disease with similar therapeutic area overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Congruence Therapeutics social profiles
Digital presenceCongruence Therapeutics compliance and trust
Trust signalCompliance2 records
Congruence Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Congruence Therapeutics leadership team
Management profileNumber of profiles
Profiles12 records
Congruence Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Congruence Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Congruence Therapeutics
What does Congruence Therapeutics do?
Congruence Therapeutics is a clinical-stage biotechnology company developing oral small molecule correctors that stabilize misfolded proteins to address the root causes of protein misfolding diseases. Its lead asset CGX-926 (oral MC4R corrector for genetic obesity) entered Phase 1/1b clinical trials in March 2026, with additional programs targeting GBA1-driven Parkinson's disease and Alpha-1 antitrypsin deficiency. Drug candidates are discovered using the proprietary Revenir™ computational platform and advanced through strategic partnerships with large pharmaceutical companies such as Ono Pharmaceutical.
Is Congruence Therapeutics a public or private company?
Congruence Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Congruence Therapeutics founded?
Congruence Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Congruence Therapeutics based?
Congruence Therapeutics is headquartered in Montréal, Canada, in the North America region.
How does Congruence Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Licensing and Royalties are the primary driver. The others are drug Sales (Future).
Who are Congruence Therapeutics's main competitors?
Direct peers on record are Schrödinger, Recursion Pharmaceuticals, Insitro, Crinetics Pharmaceuticals, Structure Therapeutics, Exscientia, Nimbus Therapeutics and Atomwise. Denali Therapeutics is listed as a broad incumbent. Maze Therapeutics is listed as an emerging player.
Does Congruence Therapeutics have an API?
No public API is recorded for Congruence Therapeutics.
What industry is Congruence Therapeutics in?
Congruence Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.